Tandem Diabetes Care climbs on FDA nod for tubeless insulin pump

By Reuters News20 hours ago Updated

** Shares of Tandem Diabetes Care TNDM.O rise 11% to $19.45

** Co says the US FDA clears Tandem Mobi as the first and only tubeless automated insulin delivery system with up to seven days of wear

** Tandem Mobi now offers both tubeless and tubed insulin delivery options, giving users flexibility to choose how they wear the pump

** Full commercial launch is planned for H1 2027 in the United States, with the sets and cartridges available exclusively through the pharmacy

** Piper Sandler analysts say the clearance is a "positive update" because investors had been wondering "why the clearance was taking so long and if something was wrong with the product," and the approval shows "that is not the case now"

** Including session moves, stock down 10% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.